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Background: S-1 is an oral ﬂuoropyrimidine. This phase II study was designed to evaluate the efﬁcacy and safety of
S-1 in patients with advanced or recurrent uterine cervical cancer.
Patients and methods: S-1 35 mg/m
2 was given twice daily for 28 days repeated every 6 weeks. Eligible patients
were women aged 20–74 years, who had Eastern Cooperative Oncology Group performance status of zero or one,
who had stage IVB or recurrent uterine cervical cancer, and who had received no more than one platinum-containing
chemotherapy regimen for stage IVB or recurrent disease. The primary end point was overall response rate (ORR)
determined by RECIST.
Results: A total of 37 patients were enrolled in the trial and 36 were eligible. The median number of cycles
administered was 4. The conﬁrmed ORR was 30.6% (95% conﬁdence interval 15.5% to 45.6%). The response rate for
patients who had received platinum-based treatment including chemoradiotherapy was 31.8% (7 of 22). After
a median follow-up duration of 25 months, the median time to progression and the median survival time were 5.2 and
15.4 months, respectively. The most frequent grade 3 or 4 adverse events were anemia (16%), anorexia (16%), and
diarrhea (22%).
Conclusions: This phase II study of S-1 in cervical cancer suggests a promising response rate and a contribution
toward prolonging survival, with modest toxic effects. Phase III studies of S-1 in patients with advanced or recurrent
cervical cancer are thus warranted.
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introduction
Cancer of the uterine cervix is the main cause of death from
gynecologic malignancy in emerging countries. In the
developed world as well, a third of women with cervical cancer
die of uncontrolled disease. Although a number of
chemotherapeutic agents have been investigated in patients
with advanced or recurrent cervical cancer, the prognosis of
those patients remains poor. Identiﬁcation of new agents with
activity in cervical cancer is needed.
S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) is an oral
ﬂuoropyrimidine consisting of tegafur [a prodrug that is
metabolized to 5-ﬂuorouracil (5-FU) in blood, largely by the
cytochrome P450 system in the liver], gimeracil (an inhibitor of
dihydropyrimidine dehydrogenase, which degrades
ﬂuorouracil), and oteracil (which inhibits the phosphorylation
of ﬂuorouracil in the gastrointestinal tract, thereby reducing the
gastrointestinal toxic effects of ﬂuorouracil) in a molar ratio of
1 : 0.4 : 1 [1]. S-1 is known to be active against gastric, head and
neck, colorectal, lung, breast, pancreatic, and biliary tract
cancers [2–9]. This phase II study was designed to evaluate the
efﬁcacy and safety of S-1 in patients with uterine cervical cancer
and is the ﬁrst exploration of S-1 for the treatment of any
gynecologic cancer. S-1 has also shown activity for cervical
cancer in preclinical study (data are available only in
investigator’s brochure); phase II study of S-1 in patients with
cervical cancer has been launched to evaluate the usefulness of
S-1 in those patients.
patients and methods
eligibility criteria
Eligible patients were aged between 20 and 74 years, had Eastern
Cooperative Oncology Group performance status of zero or one, and had
histological documented primary stage IVB or recurrent cervical carcinoma.
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Measurable lesions deﬁned unit dimensionally were ‡20 mm using
conventional imaging or ‡10 mm with spiral computed topographic scan.
Patients had not received more than one prior chemotherapy regimen since
diagnosis of metastatic or recurrent disease. Patients who were
administered in conjunction with radiation were not counted under prior
chemotherapy. Four weeks from prior chemotherapy or radiotherapy were
required before study entry. Adequate organ function was required for
study entry: neutrophil count ‡2000/ll; platelet count ‡100 000/ll;
hemoglobin ‡8.0 g/dl; serum bilirubin level £1.5 times upper limit of the
institutional normal (ULN); asparate aminotransferase, alanine
aminotransferase, and alkaline phosphatase levels £2.5 times ULN; and
serum creatinine level £ ULN. Only patients who could swallow tablets were
eligible. Patients with any of the following conditions were excluded from
the study: active infection, severe heart disease, interstitial pneumonitis,
history of hypersensitivity, malignant or benign effusions requiring
drainage, active brain metastasis, or active concomitant malignancy.
Patients receiving drugs with potential interactions with S-1 (ﬂucytosine,
warfarin, and phenytoin) were excluded. All patients gave informed consent
before entering this study, which was approved by the institutional review
boards at all participating institutions.
treatment schedule
Patients received two oral doses of S-1 35 mg/m
2 daily for 4 weeks of a
6-week cycle. As S-1 is provided in 20 or 25 mg tablets, the actual dosage
of S-1 was decided according to the patient’s body surface area as follows:
patients with a body surface area of less than 1.25 m
2 received 40 mg;
those with a body surface area of 1.25–1.5 m
2 received 50 mg; and those
with a body surface area of more than 1.5 m
2 received 60 mg. The
schedule was repeated until the occurrence of disease progression,
unacceptable toxic effects, or patient’s refusal. If a grade 3 or higher
hematological toxicity or a grade 2 or higher nonhematological toxicity
was observed, the dose was reduced from 60 to 50 mg, 50 to 40 mg, or
temporary interruption of S-1 administration was recommended. Patients
whose toxic effects necessitated a rest period of >4 weeks were withdrawn
from treatment. When initial dose was 40, 50, or 60 mg, dose escalation
could be allowed to 50, 60, and 75 mg for subsequent cycles, unless
a d v e r s ee v e n t sw e r eo b s e r v e d .
response and toxicity evaluation
The tumor response was assessed according to the guidelines of RECIST.
Target lesions included all measurable lesions up to a maximum of ﬁve
lesions per organ and 10 lesions in total. Target lesions were included the
lesions with previously irradiated area. Complete response (CR) was
deﬁned as the complete disappearance of all target and nontarget lesions,
with no development of new disease. Partial response (PR) was deﬁned as
a reduction by ‡30% in the sum of the longest diameter of target lesions.
CRs or PRs were conﬁrmed by repeat assessments carried out no <4 weeks
after the criteria for response were ﬁrst met. Progressive disease (PD) was
deﬁned as an increase ‡20% in the sum of the longest diameter of all target
lesions or the appearance of one or more new lesions and/or unequivocal
progression of existing nontarget lesions. Stable disease (SD) was deﬁned as
neither sufﬁcient lesion shrinkage to qualify for PR nor sufﬁcient increase
to qualify for PD. Best response was deﬁned as the most CR achieved by
a patient (thus, each patient had a single best response: CR, PR, SD, or PD),
and the date of best response was the date it was ﬁrst detected. Radiological
studies were repeated every two cycles. If a patient was documented as
having a CR or a PR, the response was conﬁrmed at least 4 weeks after the
ﬁrst evidence of response. An independent response review committee
(IRRC) evaluated all tumor responses after the investigators had completed
their judgment.
Toxic effects were evaluated with respect to incidence and severity using
Common Terminology Criteria of Adverse Events (version 3.0)
(www.cancer.gov/).
statistical consideration
The primary end point of this study was to assess the overall response rate
determined by the IRRC. The secondary end points were to assess duration
of response, time to response, time to progression (TTP), overall survival,
and adverse events. Assuming a response rate of 20%, the study was
designed with 80% power such that the lower limit of the 95% conﬁdence
interval (CI) for the estimate of the response rate was >0.05. A sample size
of 32 assessable patients was required. The Kaplan–Meier method was
used to determine the TTP and median survival time (MST) in the
assessable population. TTP was deﬁned as the time from the ﬁrst
medication to the date of a PD event or death (due to cervical cancer or
study drugs).
results
patient population
A total of 37 patients were entered into the study from July
2005 to September 2007 and 36 patients were eligible and
assessable. One patient had a lack of absolute neutrophil count
for eligibility criteria. All 37 patients were evaluated for safety.
Patient characteristics are listed in Table 1. More than half of
the patients had distant diseases. Seventeen patients (8 for
neoadjuvant chemotherapy, 3 for metastatic disease, and 6 for
both) received prior chemotherapy (not including
chemoradiotherapy): 14 received platinum-containing regimen
and 3 received oral 5-FU derivative drug alone. Thirteen
Table 1. Patient characteristics
Characteristic No. of patients
No. of patients entered 37
No. of patients eligible 36
Age (years)
Median 57
Range 33–72
Performance status
02 6
11 0
Histology
Squamous cell carcinoma 29
Adenocarcinoma 2
Adenosquamous 4
Small cell carcinoma 1
Site of disease
Pelvic 23
Distant 26
Both 13
Prior therapy
Prior radiotherapy 22
Prior chemotherapy
a 17
Prior chemoradiotherapy 13
Prior platinum therapy 22
aNot included chemoradiotherapy.
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therapy including chemotherapy or chemoradiotherapy was
administered for 22 patients.
A total of 167 treatment cycles (median 4, range 1–19) were
administered. Nineteen patients (53%) were subjected to dose
reduction owing to adverse events. The median relative dose
intensity was 0.83 (range 0.45–1.04).
antitumor activity
Table 2 describes the response assessment. The objective
response rate assessed by IRRC was 30.6% (95% CI 15.5% to
45.6%). The median duration of response was 134 days (range
73–553 days). The investigators identiﬁed one CR and nine
PRs. One clinical responded patient who had CR was
downgraded to PR, two clinical responded patients who had PR
were downgraded to SD and PD, respectively, and three
patients who had SD were upgraded to PR by the judgment of
IRRC. Therefore, a total of 11 patients were judged PR.
Responses according to prior therapy are listed in Table 2.
Patients who received chemotherapy alone had a response of
17.6%, patients who received chemoradiotherapy 53.8%, and
patients who received platinum-containing chemotherapy or
chemoradiotherapy 31.8%. Eighteen patients had target lesions
with previously irradiated area and ﬁve (27.8%) of them were
responded.
After a median follow-up duration of 25 months, the median
TTP was 5.2 months (95% CI 4.5–6.6 months; Figure 1) and
the MST was 15.4 months (95% CI 11.5–17.8 months; Figure
2). One-year survival was 58.3%.
safety
All 37 patients were assessed for safety. Four patients were
discontinued due to toxic effects. Adverse events are listed in
Table 3. Grade 3 or 4 hematologic toxic effects were anemia
(16%), neutropenia (8%), and thrombocytopenia (5%).
Among grade 3 or 4 nonhematologic toxic effects, the most
frequent were anorexia (16%) and diarrhea (22%). All other
grade 3 or 4 toxic effects were recorded in <10% of patients.
discussion
The prognosis of patients with advanced or recurrent cervical
cancer remains poor and there is an urgent need for novel
therapeutic agents. This current study was designed to
determine the efﬁcacy and tolerability of an oral agent of S-1
for advanced or recurrent cervical cancer and demonstrated
a higher response rate of 30.6% with modest toxic effects: grade
3 or 4 anemia (16%), anorexia (16%), and diarrhea (22%).
The most extensively studied agent in the treatment of
advanced cervical cancer is cisplatin, which has been used as
a single agent, in combination chemotherapy, or with
radiotherapy. The eligibility criteria of our study included
Table 2. Responses to S-1 according to the patient characteristics
n CR PR SD PD Response rate (95% CI)
Overall 36 0 11 18 7 30.6 (15.5–45.6)
Prior therapy
Chemotherapy 17 0 3 9 5 17.6 (0–35.8)
Chemoradiotherapy 13 0 7 5 1 53.8 (26.7–80.9)
Platinum therapy 22 0 7 10 5 31.8 (12.4–51.3)
No platinum therapy 14 0 4 8 7 28.6 (14.9–52.2)
CR, complete response; PR, partial response; SD, stable disease; PD,
Progressive disease; CI, conﬁdential interval.
Figure 1. Kaplan–Meier plot for time to progression (TTP; n = 36). CI,
conﬁdence interval.
Figure 2. Kaplan–Meier plot for overall survival (n = 36). CI, conﬁdence
interval.
Table 3. Adverse events (n = 37)
Toxicity Grade
1 2 3 4 Grade 3–4(%)
Anemia 6 11 5 1 16
Leukopenia 5 13 2 0 5
Neutropenia 6 9 3 0 8
Thrombocytopenia 6 1 1 1 5
Stomatitis 18 2 0 0 0
Anorexia 14 7 6 0 16
Nausea 21 4 1 0 3
Vomiting 12 2 1 0 3
Diarrhea 13 10 8 0 22
Hyperpigmentation 31 1 0 0 0
Skin rash 7 4 1 0 3
Fatigue 12 11 2 0 5
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Twenty-two of the 36 patients (61%) had previously received
platinum therapy including chemoradiotherapy. There may be
drug resistance to cisplatin in such patients; however, objective
responses were seen in patients who had received prior
platinum therapy. Therefore, it is suggested that S-1 is
a noncross resistant drug for cisplatin.
Several non-platinum agents, such as paclitaxel [11–13],
topotecan [14, 15], irinotecan [16, 17], vinorelbine [18–20],
capecitabine [21, 22], and ifosphamide [23–25] were found
to have moderate activity in patients with metastatic
cervical cancer. However, none of the previously reported
phase II studies of non-platinum single-agent chemotherapy
for patients with advanced cervical cancer have reported >30%
response rate, except paclitaxel and ifosphamide [26].
Paclitaxel is an active agent for cervical cancer and has
been evaluated in randomized trial. GOG 0204 compared
doublets of paclitaxel, vinorelbine, and gemcitabine plus
cisplatin with the combination of topotecan plus cisplatin,
and there was a trend favoring treatment with cisplatin/
paclitaxel for response rate, progression-free survival (PFS),
overall survival, and quality of life [27]. Ifosphamide in
combination with cisplatin was tested in randomized trial
comparing cisplatin alone and showed a better response rate
and PFS but not overall survival and including severe toxic
effects. Although our study examined a small number of
patients and the CI was wide, notable objective responses were
achieved in this single-agent chemotherapy.
Combinations of 5-FU and cisplatin yield synergistic in
preclinical studies [28, 29]. A combination therapy of S-1 and
cisplatin has been studied in other malignancies, including
gastric cancer, lung cancer, and head and neck cancer [30–32].
Phase III trial comparing S-1 in combination with cisplatin
versus S-1 alone in advanced gastric cancer demonstrated
a signiﬁcant beneﬁt for combined S-1 plus cisplatin in response
rate, PFS, and overall survival [33]. Based on the promising
activity of S-1 in the present phase II study, and the experience
with S-1 plus cisplatin in other malignancies, we have started
phase III trial of S-1 plus cisplatin compared with single-agent
cisplatin for metastatic cervical cancer in an Asian trial,
including Japan, Korea, and Taiwan.
In conclusion, S-1 is active in patients with metastatic
cervical cancer and well tolerated. S-1 plus cisplatin has now
entered a prospective randomized phase III trial.
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